Fulgent Genetics (FLGT) Receivables - Net (2015 - 2026)

Fulgent Genetics has disclosed Receivables - Net across 12 years of filings, most recently posting $69.3 million for Q1 2026.

• Receivables - Net for Q1 2026 came in at $69.3 million, down 3.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $69.3 million (down 3.08% YoY), and the FY2025 annual result was $84.8 million, up 22.81% from the prior year.
• Receivables - Net came in at $69.3 million for Q1 2026 at Fulgent Genetics, down from $84.8 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $160.3 million in Q1 2022 to a low of $34.8 million in Q2 2023.
• The 5-year median for Receivables - Net is $69.0 million (2024), against an average of $72.8 million.
• Across the five-year window, Receivables - Net slumped 73.89% in 2023 and surged 62.52% in 2024, its largest moves.
• Fulgent Genetics' Receivables - Net stood at $52.7 million in 2022, then retreated by 3.07% to $51.1 million in 2023, then jumped by 34.99% to $69.0 million in 2024, then grew by 22.81% to $84.8 million in 2025, then fell by 18.27% to $69.3 million in 2026.
• The last three Receivables - Net figures came in at $69.3 million (Q1 2026), $84.8 million (Q4 2025), and $71.2 million (Q3 2025), per Business Quant data.